HOME >> BIOLOGY >> NEWS
Memorial Sloan-Kettering Investigators

hat determines which patients respond to RA and which ones don't have identified a genetic difference between the two groups. APL patients who do well on RA treatment have leukemia that results from the fusion of two genes called PML and RAR-alpha (PML-RAR ), while the leukemia of patients who are resistant to RA is caused by a fusion of the genes PLZF and RAR-alpha (PLZF-RAR ).

To study these minute genetic differences further, Dr. Pandolfi and his colleagues developed two groups of mice: One group harbored the PML-RAR gene fusion, while a second group had the PLZF-RAR gene fusion. Both groups of mice developed APL similar to that seen in humans. In normal cells, certain proteins called transcription factors -- such as RAR -- turn on the expression of other genes with specific functions, such as controlling cell growth and maturation. Using advanced analytical techniques, Dr. Pandolfi's group showed that unlike RAR , proteins produced by the PML-RAR and PLZF-RAR gene fusions turned off, or "repressed," the expression of the cell's genes that normally prompt a cell to mature into a healthy, functioning white blood cell. Because these genes were turned off, the cells didn't mature, and leukemia developed. Moreover, the investigators found that PML-RAR and PLZF-RAR were acting as transcription repressors because of their ability to interact with other proteins. In PML- RAR , these interactions were broken apart by RA, while in PLZF-RAR they were insensitive to RA, explaining why retinoic acid works in some APL patients but not others.

Armed with this new knowledge, the MSKCC researchers set out to find ways to undo this chain of events. They knew that genetic material in a chromosome is tightly held together by proteins called histones. However, histones prevent individual gene expression. Previous studies of histones have shown that transcription repressors may work by favoring the place
'"/>

Contact: Kelli Stauning
stauningk@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
26-Jan-1998


Page: 1 2 3 4

Related biology news :

1. Veterinary Memorial Fund transforms grief into promise
2. Andres Vazquez-Torres honored with 2004 Merck Irving S. Sigal Memorial Award
3. American Society for Microbiology honors Timothy Yahr with 2004 Merck Irving S. Sigal Memorial Award
4. Childrens Memorial, TGen announce partnership
5. Webcast of NSF Director Rita Colwells Chafee Memorial Lecture
6. Director of Emory Vaccine Center to give Wistar Institutes 1999 Tadeusz J. Wiktor Memorial lecture
7. Snapshot of new drug marks a major advance by Memorial Sloan-Kettering researchers
8. Chern Memorial Award Presented To Wistar Institute Postdoctoral Fellow
9. APS announces four 2004 Young Investigators awards
10. EMBO Young Investigators 2000 2002
11. Investigators use guilt-by-association strategy to track potential cancer causing genes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/8/2016)... , March 8, 2016   Valencell ... technology, today announced it has secured $11M in ... GII Tech, a new venture fund being launched ... additional participation from existing investors TDF Ventures and ... funds to continue its triple-digit growth and accelerate ...
(Date:3/3/2016)... MONTEREY, Calif. , March 3, 2016 /PRNewswire/ ... Partner, launched this week highlighting advancements in flexible, ... – a record setting attendance - have gathered ... in this fast-growing field of electronics. The Flex ... a focal point for companies, R&D organizations, and ...
(Date:3/2/2016)... March 2, 2016 ... addition of the  "Global Biometrics Market in ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , Global biometrics ... at a CAGR of around 27%   ... has announced the addition of the  "Global ...
Breaking Biology News(10 mins):
(Date:5/4/2016)... N.J. , May 4, 2016  Bayer ... its oncology compound Stivarga ® (regorafenib) tablets ... carcinoma (HCC) has met its primary endpoint of ... study, called RESORCE, evaluated the efficacy and safety ... has progressed after treatment with sorafenib. The safety ...
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... growth, has leveraged recent innovations in biotechnology to help treat hormonal and stress ... hair loss, Nutrafol® has captured the hearts of key opinion leaders in the ...
(Date:5/3/2016)... ... 03, 2016 , ... Leading CEOs from biotech, pharmaceutical, and ... June 1st at The Four Seasons Hotel Boston. , The Boston CEO Conference ... exclusive access to key decision makers who influence deal making and investment. Attendees ...
(Date:5/3/2016)... -- - And Other Rising Companies - ... Competitor Biologics  - Biosimilar Drug Producers - ... Who are the most important and promising ... sales potentials? Discover, in our updated survey, organisations, outlooks ... revenue forecasting. Visiongain,s new study ...
Breaking Biology Technology:
Cached News: